---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-193925"
form_type: "8-K"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:57:29.913715+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Indivior Q1 net revenue $317M (+19% YoY); raises FY2026 guidance

## Summary
- Q1 GAAP net income $89M ($0.69 EPS); non-GAAP net income $123M ($0.96 EPS).
- SUBLOCADE net revenue $232M (+32% YoY) driven by 20% dispense unit growth.
- Record Q1 adjusted EBITDA $164M (+112% YoY); cash and investments $201M.
- Raised FY2026 guidance: net revenue $1.215-1.285B; adj. EBITDA $620-660M.
- Discontinued INDV-6001 development; INDV-2000 failed Ph2 OUD endpoint.

## SEC filing metadata
- accession: 0001193125-26-193925
- form_type: 8-K
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000119312526193925/0001193125-26-193925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000119312526193925/d40828d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-193925
- JSON: https://secwatch.observer/filing/0001193125-26-193925.json
- Plain text: https://secwatch.observer/filing/0001193125-26-193925.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.